Familial hypercholesterolemia 25 years after. II. forms with normal LDL receptor;L'HYPERCHOLESTEROLEMIE FAMILIALE 25 ANS APRES II. FORMES NON LIEES AU RECEPTEUR DES LDL

Medecine/Sciences

Volumn 13, Issue 12, 1997, Pages 1409-1418

  Rabès, Jean Pierre ^b   Varret, Mathilde ^a   Boileau, Catherine ^b  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN RECEPTOR;

ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL MODEL; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE FREQUENCY; GENE MUTATION; GENETIC HETEROGENEITY; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOTE; HUMAN; HUMAN CELL; LIGAND BINDING; MAJOR CLINICAL STUDY; MARKER GENE; MOLECULAR EVOLUTION; PHENOTYPE; POPULATION GENETICS; RECEPTOR AFFINITY; RECESSIVE INHERITANCE; REVIEW;

EID: 0030725327     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/572     Document Type: Review

References (40)

1. Soria L, Ludwig E, Clarke H, Vega G, Grundv S, McCarthy B. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989; 86: 587-91.
2. Pullinger C, Hennessy L, Chatterton J, Lin W, Love J, Mendel C, Frost P, Malloy M, Schumaker V, Kane J. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decrease LDL receptor binding affinity. J Clin Invest 1995; 95: 1225-34.
3. Gaffney D, Reid J, Cameron I, Vass K, Caslake M, Shepherd J, Packard C. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 1025-9.
4. Sivaram P, Vanni-Reyes T, Goldberg I. Endothelial cells synthesize and process apolipoprotein B. J Biol Chem 1996; 271: 15261-6.
5. Benne R. RNA editing: how a message is changed. Curr Opin Genet Dev 1996; 6: 221-31.
6. Knott T, Pease R, Powell L, Wallis S, Rall S, Innerarity T, Blackhart B, Taylor W, Marcel Y, Milne R, Johnson D, Fuller M, Lusis A, McCarthy B, Mahley R, Levy-Wilson B, Scott J. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature 1986; 323: 734-8.
7. Milne R, Théolis R Jr., Maurice R, Pease R, Weech P, Rassart E, Fruchart J, Scott J, Marcel Y. The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem 1989; 264: 19754-60.
8. 13CNMR evidence that substitution of glutamine for arginine 3500 in Familial Defective apolipoprotein B-100 disrupts the conformation of the receptor-binding domain. J Biol Chem 1991; 266: 2701-4.
9. 3531 → Cys mutations in a french population. Hum Mutat 1997; 10: 160-3.
10. (3500) → glutamine associated with familial defective apolipoprotein B-100. J Lipid Res 1993; 34: 799-805.
11. Bersot T, Russell S, Thatcher S, Pomernacki N, Mahley R, Weisgraber K, Innerarity TL FC. A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B100 in a Chinese man discovered during a study of the prevalence of this disorder. J Lipid Res 1993; 34: 1149-54.
12. Tybjærg-Hansen A, Humphries S. Familial defective apolipoprotein B-100. a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis 1992; 96: 91-107.
13. Arnold K, Balestra M, Krauss R, Curtiss L, Young S, Innerarity T. Isolation of allelespecific, receptor-binding-defective low density lipoproteins from familial defective apolipoprotein B-100 subjects. J Lipid Res 1994; 35: 1469-76.
14. Gallagher J, Myant N. The affinity of low-density lipoproteins and of very-low-density lipoprotein remuants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100. Atherosclerosis 1995; 115: 263-72.
15. Pietzsch J, Wiedemann B, Julius U, Nitzsche S, Gehrisch S, Bergmann S, Leonhardt W, Jaross W, Hanefela M. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approch. J Lipid Res 1996; 37: 2074-87.
16. Defesche J, Pricker R, Hayden M, van der Ende B, Kastelein J. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Intern Med 1993; 153: 2349-56.
17. Myant N. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1-18.
18. Miserez A, Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 1719-29.
19. Kotze M, Peeters A, Langenhoven E, Wauters J, Van Gaal L. Phenotypic expression and frequency of familial defective apolipoprotein B-100 in Belgian hypercholesterolemics. Atherosclerosis 1994; 111: 217-25.
20. Goldstein J, Brown M. Familial Hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, eds. The metabolic basis of inherited diseases, 6th ed. New York: McGraw-Hill, 1989: 1215-50.
21. Geisel J, Schleifenbaum T, Oette K, Weibhaar B. Familial defective apolipoprotein B-100 in 12 subjects and their kindred. Eur J Clin Chem Clin Biochem 1992; 30: 729-36.
22. Myant N, Gallagher J, knight B, McCarthy S, Frostegard J, Nilsson J, Hamsten A, Talmud P, Humphries S. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arterioscler Thromb 1991; 11: 691-703.
23. Davignon J, Dufour R, Roy M, Bétard C, Ma Y, Ouellette S, Boulet L, Lussier-Cacan S. Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in then absence of an LDL-receptor defect within a Canadian kindred. Eur J Epidemiol 1992; 8: 10-17.
24. Benlian P, de Gennes J, Dairou F, Hermelin B, Ginon I, Villain E, Lagarde J, Federspiel M, Bertrand V, Bernard C, Bereziat G. Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100. Hum Mutat 1996; 7: 340-5.
25. Hansen P, Norgaard-Petersen B, Meinertz H, Jensen H, Hansen A, Klausen I, Gerdes L, Faergeman O. Incidence of the apolipoprotein B-3500 mutation in Denmark. Clin Chim Acta 1994; 230: 101-4.
26. Miserez A, Laager R, Chiodetti N, Keller U. High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 1994; 35: 574-83.
27. Hansen P, Meinertz H, Jensen H, Fruergaard P, Launbjerg J, Klausen I, Lemming L, Gerdes U, Gregersen N, Faergeman O. Characteristics of 46 heterozygous carriers and 57 unaffected relatives in five Danish families with Familial defective apolipoprotein B-100. Arterioscler Thromb 1994; 14: 207-13.
28. Tybjærg-Hansen A. Rare and common mutations in hyperlipidemia and atherosclerosis. With special reference to familial defective apolipoprotein B-100. Scand J Clin Lab Invest 1995; 55: 57-76.
29. Overturf M, Loose-Mitchell D. In vivo model systems: the choice of the experimental animal model for analysis of lipoproteins and atherosclerosis. Curr Opin Lipidol 1992; 3: 179-85.
30. Breslow J. Mouse models of atherosclerosis. Science 1996; 272: 685-8.
31. Xiong W, Zsigmond E, Gotto A, Reneker L, Chan L. Transgenic mice expressing full-length human apoliprotein B-100 : full-length human apoliprotein B mRNA is essentially not edited in mouse intestine or liver. J Biol Chem 1992; 267: 21412-20.
32. Lestavel-Delattre S, Benhamamouch S, Agnani G, Luc G, Bard J, Brousseau T, Billardon C, Kusnierz J, De Gennes J, Fruchart J, Clavey V. Evidence of non-deficient low-density lipoprotein receptor patients in a pool of subjects with clinical Familial hypercholesterolemia profile. Metabolism 1994; 43: 397-402.
33. Masana L, Joven J, Rubiés-Prat J, Lewis B. Low density lipoprotein metabolism and receptor studies in a patient with pseudohomozygous familial hypercholesterolemia. Acta Paediatr Scand 1990; 79: 475-6.
34. Koch M, Pfohl M, Enderle M, Schnauder G, Seif F. Detection of the apolipoprotein B-100 arg(3500) → Gln mutation in familial defective apoB-100 by temperature-gardient gel electrophoresis. Z Gastroenterol 1996; 34: 16-8.
35. Geisel J, Holzem G, Schleifenbaum T, Oette K. Screening for mutation in the LDL receptor gene and apolipoprotein B-100 gene in 218 patients with severe hypercholesterolemia. Z Gastroenterol 1996; 34: 14-5.
36. Horinek A, Slezka V, Sobra J, Ceska R. Moznosti DNA analyzy u heterozygotu familiarni hypercholesterolemie. Cas Lek Cesk 1995; 134: 234-9.
37. Brousseau T, Lecerf J, Luc G, Devukler B, Fruchart J, Amouyel P. Recherche de la mutation Arg3500 → Gln de l'apolipoprotein B. Presse Med 1995; 24: 769-72.
38. Eggertsen G, Eriksson M, Wiklund O, Iitiä A, Olofsson S, Angelin B, Berglund L. Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100. J Lipid Res 1994; 35: 1505-8.
39. Morash B, Guernsey D, Tan M, Dempsey G, Nassar B. Detection of Familial defective apolipoprotein B-100 among patients clinically diagnosed with heterozygous familial hypercholesterolemia in maritime Canada. Clin Biochem 1994; 27: 265-72.
40. Leren T, Rodningen O, Tonstad S, Rosby O, Urdal P, Ose L. Identification of the apoB-3500 mutation in the Norwegian population. Scand Clin Lab Invest 1995; 55: 217-21.